These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 5361014)

  • 21. [Association of neomycin sulfate and ethyl-p-chlorophenoxybutyrate in the treatment of dyslipemia].
    Bertulla A; Bertamino V; Solari E
    Ateneo Parmense 1; 1971; 42(2):103-14. PubMed ID: 5154400
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) and of clofibrate on the lipids of normal and hypercholesteremic rats.
    Berger FM; Douglas JF; Lu GG; Ludwig BJ
    Proc Soc Exp Biol Med; 1969 Oct; 132(1):293-7. PubMed ID: 5344849
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of certain hypocholesterolemic agents on hepatic delta-aminolevulinic acid synthetase levels in mice.
    Weissman EB; Cheng LC; Orten JM
    Proc Soc Exp Biol Med; 1974 Feb; 145(2):438-41. PubMed ID: 4814138
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of atromid S on certain fractions of collagen from the aortic wall of rats being on atherogenic diet].
    Hanzlik J; Lopatyński J; Tyburczyk W
    Pol Tyg Lek; 1967 Jan; 22(2):48-50. PubMed ID: 6040630
    [No Abstract]   [Full Text] [Related]  

  • 25. The hypocholesterolemic action of eritadenine in the rat.
    Takashima K; Izumi K; Iwai H; Takeyama S
    Atherosclerosis; 1973; 17(3):491-502. PubMed ID: 4736648
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs.
    Barrett AM; Thorp JM
    Br J Pharmacol Chemother; 1968 Feb; 32(2):381-91. PubMed ID: 4296427
    [No Abstract]   [Full Text] [Related]  

  • 27. Microbodies in experimentally altered cells. II. The relationship of microbody proliferation to endocrine glands.
    Svoboda D; Azarnoff D; Reddy J
    J Cell Biol; 1969 Mar; 40(3):734-46. PubMed ID: 5765763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasma lipid-normalizing activity of the combination of ethylchlorophenoxyisobutyrate and duodenal sulfomucopolysaccharide extract].
    Sabella G
    Farmaco Prat; 1967 Dec; 22(12):786-94. PubMed ID: 4238407
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of Regelan (Atromid-S) on serum lipids and platelet aggregation in occlusive arterial disease].
    Fischer M; Irsigler K
    Int Z Klin Pharmakol Ther Toxikol; 1968 Jan; 1(3):248-51. PubMed ID: 4880993
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of chlorophenoxyisobutyrate on plasma composition of cholesteryl esters and on levels of neutral lipids.
    Hagopian M; Robinson RW
    J Atheroscler Res; 1968; 8(1):21-7. PubMed ID: 5642104
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum phospholipid alterations and their control by chlorophenoxyisobutyrate and betabenzalbutyrate in puromycin aminonucleoside induced nephrotic syndrome in the rat.
    Gallt C; Edwards KD; Paoletti R
    Life Sci II; 1970 May; 9(9):523-34. PubMed ID: 5452796
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of clofibrate on thrombocyte adhesivity and some coagulation parameters.
    Dybkaer R; Geill T
    Gerontol Clin (Basel); 1967; 9(3):157-66. PubMed ID: 6055296
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of ethyl-p-chlorophenoxyisobutyrate, clofibrate, on the plasma and red blood cell free fatty acids of the rat.
    Cenedella RJ; Jarrell JJ; Saxe LH
    J Atheroscler Res; 1968; 8(6):903-11. PubMed ID: 5707796
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hypocholesterolemic activity of the combination of ethyl-p-chlorophenoxyisobutyrate and extractive sulfomucopolysaccharide].
    Nicrosini F; Butti A; Pasotti C
    Farmaco Prat; 1968 May; 23(5):256-62. PubMed ID: 4238576
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of clofibrate on serum and hepatic lipids in nephrotic rats.
    Hoak JC; Connor WE; Armstrong ML; Warner ED
    Lab Invest; 1968 Oct; 19(4):370-5. PubMed ID: 5699117
    [No Abstract]   [Full Text] [Related]  

  • 36. Degradation kinetics of liver catalase in rats treated with ethyl-alpha-p-chlorophenoxyisobutyrate.
    Chiga M; Reddy J; Svoboda D
    Lab Invest; 1971 Jul; 25(1):49-52. PubMed ID: 5555696
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of ethyl chlorophenoxyisobutyrate on postprandial lipemia].
    Beaumont JL; Menard J; Beaumont V
    Rev Atheroscler (Paris); 1966; 8(1):21-6. PubMed ID: 5960551
    [No Abstract]   [Full Text] [Related]  

  • 38. Decrease of ethanol-induced fatty liver by ethyl alpha-p-chlorophenoxyisobutyrate.
    Spritz N; Lieber CS
    Proc Soc Exp Biol Med; 1966 Jan; 121(1):147-9. PubMed ID: 5902917
    [No Abstract]   [Full Text] [Related]  

  • 39. The hypocholesterolemic effect of phenyramidol.
    Schrogie JJ
    Clin Pharmacol Ther; 1966; 7(6):723-6. PubMed ID: 5918008
    [No Abstract]   [Full Text] [Related]  

  • 40. Observations on the effect of ethyl a-p chlorophenoxyisobutyrate (CPIB) therapy on serum lipid levels and on diabetic and some other retinopathies.
    Vannas S; Esilä R; Tuovinen E
    Acta Ophthalmol (Copenh); 1968; 46(2):162-70. PubMed ID: 5755673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.